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1. Introduction
Targeted therapy in cancer has led to intensive searches for the molecular pathways of ma‐
lignant transformation [1]. In gynecologic malignancies, BRCA 1 and BRCA 2 gene muta‐
tions on chromosomes 17 and 13 respectively were identified in the 1990s [2]. Since then,
intensive investigation of the pathways for these genes has led to a wealth of information
about molecular pathways [3]. The understanding of these molecular pathways has led in
turn to the development of novel targeted therapies for women with identified gene muta‐
tions [4]. This review reviews the current knowledge of the subset of women with BRCA
gene mutations. The characteristics of BRCA deficiency including genetic background and
current chemotherapeutic options including mechanisms of resistance are discussed as well.
Finally, the data on emerging targeted therapeutic strategies with poly-ADP-ribose-poly‐
merase (PARP) inhibitors and specific PARP clinical trials are reviewed.
2. BRCA genetic background
Hereditary Breast and Ovarian Cancer Syndrome (HBOCS) is characterized by a few distinct
features: earlier age of cancer onset, higher incidence of bilateral disease, higher incidence of
other cancers, and inheritance in an autosomal dominant pattern [5]. A number of genes, as
well as associated syndromes, have been implicated in HBOCS, but none more so than the
BRCA genes. Individuals with impaired BRCA protein function have a 50-85% lifetime risk
of developing breast cancer and 10-40% lifetime risk of developing ovarian cancer [6]. Al‐
though deleterious mutations in either of the 2 BRCA genes significantly increases one’s risk
for breast and ovarian cancer, mutations in these genes account for only about 5-10% of all
breast and ovarian cancer cases [7]. Because of genetic testing, the families of the subset of
women with BRCA associated cancers can be tested and early intervention is a possibility
[8]. These include tamoxifen therapy, bilateral prophylactic oophorectomy, prophylactic
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contralateral mastectomy and combinations of these strategies. Such interventions have
been shown to offer substantial life expectancy gain for young women with BRCA associat‐
ed early stage cancer. Currently, treatment of BRCA-associated breast and/or ovarian cancer
is no different than that for the general population. Survival data of BRCA positive patients
with ovarian cancer suggests that they have prolonged disease free intervals and overall
longer survival than their wild-type counterparts [9].
The Breast Cancer Susceptibility genes (BRCA 1 and 2) are considered tumor suppressors,
whose job it is to maintain appropriate cell growth, ultimately by upholding genomic stability
[10]. No single unified theory exists regarding the action of the BRCA genes. While disruption
of either of the BRCA genes demonstrates similar pathophysiological manifestations, they are
indeed unique. They lie on 2 separate chromosomes, each have unique primary sequences, and
ultimately carry out their responsibilities via discrete (proposed) mechanisms. Furthermore,
their unique mechanisms of action give them distinct characteristics that coincide with dis‐
tinct risks and prognoses with gene disturbance. Both BRCA genes share a relationship with
the gene RAD51, which encodes a protein responsible for assisting in repair of DNA double
strand breaks via homologous recombination. When there is a double strand break in the ge‐
netic sequence,  sequenceX  of  a specific chromatid,  homologous recombination provides a
means for the exchange of the same genetic sequence, sequenceX, from the healthy homolo‐
gous sister chromatid to the damaged one. Rad51 is one of the most important players in HRR.
It assists in the search for homology and strand pairing, and its responsibilities are ultimately
complemented by the proteins encoded by the 2 BRCA genes [11]. Studies suggest that BRCA2
regulates the intracellular transport and function of RAD51, as well as the enzymatic activity of
the RAD51 protein [12]. The relationship between BRCA1 and RAD51 is less clear. There is evi‐
dence that BRCA1 physically associates with proteins other than RAD51, creating a complex
likely responsible for the creation of resected single-stranded DNA at double strand repair
sites [13]. Further data supports BRCA1’s role in activation of DNA damage checkpoints.
There is also evidence that supports BRCA1’s role in altering chromatin structure upon DNA
damage to allow easier access for repair.
Figure 1. Role of BRCA proteins in Homologous Recombination Repair
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(See Figure 1) 1) DNA damage triggers activation of the ataxia-telangiectasia mutated ser‐
ine-protein kinase as well as the ataxia-telangiectasia and Rad3 related protein kinase [14]. 2)
Once activated, these enzymes phosphorylate and activate a number of intracellular items,
including the BRCA1 protein, Checkpoint kinase 2 (which also activates BRCA1), BRCA2,
the Fanconi anemia protein complex, H2AX histones involved in forming nuclear foci cru‐
cial for DNA repair, and a few others [15]. 3) The H2AX histones co-localize and join with
other proteins to form nuclear foci at the sites of DNA damage. These other proteins include
a tumor binding protein 53BP1, the nuclear factor with BRCT domains protein 1 NFBD1,
checkpoint kinase 2, and Nijmegen breakage syndrome 1 protein Nibrin. 4) Nibrin is part of
the MRN complex, which also includes Rad50 and MreII. The MRN complex is important in
initial processing of double stranded DNA breaks. It directs the cellular process to continue
via homologous recombination or non-homologous end joining. BRCA1 plays a part in reg‐
ulating the MRN complex by inhibiting MreII [16]. This action depresses the NHEJ pathway
and stimulates the Rad51 pathway favoring homologous recombination. 5) BRCA1 also acti‐
vates BRCA1 interacting protein C-terminal helicase 1 (BRIP1), which unwinds DNA
strands near sites of damage allowing other repair machinery to access the damaged sites.
The gene that encodes BRIP1 may also act as an oncogene in ovarian cancer. 6) Activation of
Rad51 allows it to form a complex with BRCA2 and Fanconi anemia complementation
group D2 protein, FANCD2 [17]. This complex is a key player in homologous recombination
repair as it is involved in searching for homology as well as strand pairing, while causing S-
phase and G2 arrest [18]. 7) Certain homologous recombination repair (HRR) promoting ac‐
tivities of BRCA1 are amplified when it forms a complex with BRCA1 associated RING
domain protein 1, BARD1 [19]. This complex may also play a role in mismatch repair via
downstream action [20].
3. Associated breast and ovarian cancer
Inheritance of a damaging mutation in either BRCA gene can cause disruption of the
smoothly regulated replication process of the body’s cells, potentially leading to cancer.
Though the mechanism is poorly understood, mutations in the BRCA genes show preferen‐
tial deleterious consequences in breast and ovarian tissues. In the general population, the
lifetime prevalence of breast cancer is 12% and ovarian cancer 1.4% [21]. A mutation in the
BRCA1 gene puts an individual at a 50-85% lifetime risk of developing breast cancer and a
15-40% risk of developing ovarian cancer. BRCA2 mutation carriers have a 50-85% lifetime
risk of developing breast cancer and a 10-20% risk of developing epithelial ovarian cancer.
In addition, BRCA mutations are associated with bilateral disease, cancer at a younger age
(BRCA1), autosomal dominant inheritance pattern, increased risk of male breast cancer
(BRCA2), and increased risk of cancer in other organs [22,23]. Specifically, BRCA positive in‐
dividuals are at increased risk of epithelial ovarian cancer (EOC), which behaves differently
than EOC seen in the general population. Both BRCA1 and 2 carriers have an improved
prognosis when compared to their wild-type counterparts. A pooled analysis of 26 observa‐
tional studies on the survival of women with ovarian cancer, including 1213 EOC cases
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showed that among patients with invasive EOC, having a BRCA mutation was associated
with improved 5-year overall survival, with BRCA2 carriers having the best prognosis [9].
See Table 1.
BRCA 1 carriers BRCA 2 carriers Non-Carriers
Inheritance Auto-Dominant Auto-Dominant Sporadic
Prevalence of EOC 39% 22% 1.4%
Mean age of onset 54 62 63
Tumor: Stage @ surgery Advanced Advanced Advanced
Histolology Serous Serous Serous
Differentiation Mod-Poor Mod-Poor Mod-poor
Treatment Surgery + Chemo Surgery + Chemo Surgery + Chemo
Recurrence-Free interval 14 months 14 months 7 months
5-year Survival 44% 52% 36%
Other malignancies Breast, gastric
hepatobiliary, renal,
testicular, leukemia
Breast (including
higher incidence of
male breast
cancer), prostate,
pancreatic
Table 1. Characteristics of BRCA 1/2 associated Epithelial Ovarian Cancer (EOC) [9,24,25]
BRCA1 associated breast cancers tend to be of the triple-negative type which is significant
because it lacks the 3 biomarkers most commonly implicated in breast cancer, the estrogen
and progesterone receptors and the human epidermal growth factor receptor 2 (Her2/neu)
[26]. The presence of these biomarkers helps in the guidance of treatment options. Estrogen/
progesterone positive breast cancers are typically treated with hormonal therapy (in con‐
junction with surgery/radiation), and Her2/neu positive breast cancers are treated with an
agent that specifically targets the Her2 receptor, such as Herceptin. When these 3 biomark‐
ers are negative in a newly diagnosed breast cancer, the treatment approach becomes more
complicated and prognosisis poor. On the other hand, BRCA2 associated breast cancer is
typically hormonal in nature [22]. Current evidence suggests no difference in overall prog‐
nosis of breast cancers in BRCA carriers compared to sporadic breast cancers, but BRCA de‐
ficiency does appear to be predict chemo-sensitivity [27].
4. BRCAness
The term "BRCAness" describes a subset of women with sporadic EOC who display similar
phenotypic characteristics to those with a hereditary BRCA mutation [28]. It is widely ac‐
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cepted that a deleterious BRCA mutation adversely affects homologous recombination.
While the BRCA genes indeed play a very important role in homologous recombination,
they are not the only key players. A defect or hiccup in any of the other genes involved in
homologous recombination would in theory, affect this process. This describes the notion of
BRCAness: Individuals with structurally healthy BRCA genes that are functionally incapa‐
ble of carrying out homologous recombination due to a defect elsewhere that hinders the en‐
tire process. In fact, about 40-50% of ovarian cancer cases have shown to have some defect in
homologous recombination, with a large number of these being associated with BRCA-relat‐
ed defects. See Figure 2.
Figure 2. illustrates the molecular profile of serous ovarian cancer. BRCA1 germline, BRCA2 germline, BRCA1 somatic,
BRCA2 somatic, BRCA1 hypermethylation, EMSY amplification and PTEN loss have all been shown to lead to impaired ho‐
mologous recombination, comprising about half of all cases [29]. Sporadic ovarian cancer mutations that affect homolo‐
gous recombination are clinically significant because they tend to behave like the BRCA cancers. This special sub-group of
epithelial ovarian cancer patients show similar therapeutic response and prognosis as their BRCA mutant counterparts
which includes improved sensitivity to platinum as well as improved 5 year survival [30]. A few studies have attempted to
reveal the mechanism behind BRCAness on a genetic level. There is some data to suggest that transcriptional or post-tran‐
scriptional repression of the BRCA1 gene is responsible for such sporadic tumors. For example, hypermethylation of a pro‐
motor region upstream from BRCA1 gene that leads to inactivation of BRCA1 protein, causes impaired homologous
recombination leading to a sporadic “BRCAness” with an intact yet silenced BRCA1 gene [31].
It should be noted that the specific target of the PARP inhibitor class is not only BRCA mu‐
tant cancers; however, it encompasses all that fall under the umbrella of impaired homolo‐
gous recombination. So in theory, PARP inhibitors should show efficacy in a number of
sporadic cancers as well, specifically those that elicit “BRCAness” characteristics [32].
PARP Inhibitors in Ovarian Cancer
http://dx.doi.org/10.5772/52888
307
5. Mechanisms of resistance
Currently, there is no difference in management of EOC between BRCA positive patients
and BRCA wild type patients. Maximal surgical cytoreduction, with or without neoadjuvant
chemotherapy, is the standard initial approach, excluding individuals who are not good sur‐
gical candidates or whose disease precludes optimal cytoreduction [34]. The typical chemo‐
therapeutic regimen is a taxane/platinum based combination therapy. The standard post-
operative approach would be 6 cycles (21 days each) of IV paclitaxal with carboplatin [35]
The 5-year survival and prognosis for advanced stage ovarian cancer, in BRCA or wild-type
carriers ranges between 10 and 25 percent. Such poor prognosis is due to an incredibly high
recurrence rate of advanced ovarian cancer. The extremely high rate of recurrence is due to
the development of drug resistance [36]. Initially, 75% of patients with advanced disease
show response to chemotherapy, while the remaining 25% show intrinsic resistance. How‐
ever, most of the population with initial chemosensitivity will show relapse within 2 years
of initial treatment. Patients who have a shorter interval from their last course of chemother‐
apy to relapse will show decreased response with future courses [37]. For women who re‐
lapse within 6 months of treatment completion, there is a less than 10% chance of
responding to any future therapies. For women whose disease recurs more than 6 to 12
months after initial therapy, chemotherapy includes platinum-based, multi-agent regimens.
These women are considered partially platinum sensitive (relapse within 6-12 months) or
platinum sensitive (relapse greater than 12 months after initial treatment). For patients who
are platinum resistant (relapse within 6 months) or platinum refractory (no initial response),
sequential single agents, such as pegylated liposomal doxorubicin hydrochloride or topote‐
can are suggested [38]. The slightly superior prognosis of BRCA patients compared to spora‐
dic EOC is likely related to their greater sensitivity to platinum based therapy [33].
However, despite initial chemo-sensitivity of BRCA carriers, they will ultimately develop to
platinum resistant recurrent ovarian cancer.
PARP Inhibitors are not unlike the standard therapies for ovarian cancer, in that they too
have shown evidence of resistance. Theoretically, their maximum potential is seen in cells
with impaired homologous recombination. Researchers have hypothesized that resistance to
PARP Inhibitors is through DNA repair mechanisms that actually correct the homologous
recombination process. Through compensatory mutations, the initial mutational reading
frame is corrected to a reading frame that actually produces a wild type BRCA protein [39].
A restoration in BRCA function would further contribute to platinum resistance and create
PARP inhibitor resistance. This will need further investigations.
6. PARP inhibitors
PARP proteins are involved in a number of cellular processes, including DNA replication,
transcriptional regulation, and DNA damage repair [40].Of the numerous PARP proteins
detected, PARP1 and PARP2, which are associated with DNA stability, have been intensive‐
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ly studied. The PARP enzyme regulates cellular responses to DNA damage, and plays an
important role in the repair of single-stranded breaks by excision repair [41]. See Figure 3.
Figure 3. Role of Poly (ADP-ribose) polymerase in Base Excision Repair
The base excision repair (BER) pathway recognizes and removes damaged or inappropriate
bases [42]. Damage specific glycosylases recognize the presence of a faulty base and imme‐
diately removes it. This leads to the formation of a potentially cytotoxic apurinic or apirimi‐
dinic (AP) site. Such sites are then processed by an AP endonuclease, which creates a strand
break in the DNA. The enzyme Poly (ADP-ribose) polymerase binds to the strand break and
relaxes the chromatin structure to allow for easier access of the BER machinery. Then, PARP
transfers ADP-ribose units from NAD+ to nuclear target proteins, histones, and itself. This
forms long and branched polymers of poly (ADP-ribose) on the PARP enzyme, that act as a
signaling mechanism to recruit the BER machinery, including adaptor factor XECC1, PCNA,
RFC, ligase III and DNA polymerase β. The BER complex assembles at the site of damage
and facilitates repair in a coordinated fashion. Once complete, the complex disperses [43].
When PARP is inhibited, common single-strand breaks are converted into double-stranded
breaks during DNA replication. In normal wild type cells, homologous recombination is the
most common mechanism of repair in these double-stranded breaks which provides a safety
net in maintaining genomic stability. In the presence of a deleterious BRCA gene, homolo‐
gous recombination is impaired. These cells and the tumors that they form have increased
susceptibility to PARP inhibition, which leads to decreased chromosomal stability and, ulti‐
mately, cell death. See Figure 4.
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Figure 4. Synthetic Lethality of PARP Inhibition
PARP inhibitors are also hypothesized to increase cytotoxicity of chemotherapeutic agents.
Cells treated with chemotherapy, especially platinum based agents, ultimately attain resist‐
ance by altering DNA repair processes [44]. It is hypothesized that through PARP inhibition,
cells with faulty BRCA function could be prevented from repairing chemotherapy -induced
DNA damage [45,46]. Clinical trials have examined PARP inhibitors as single agents in pa‐
tients with impaired homologous recombination, as well as in combination with chemo-ra‐
diation therapy.
7. Clinical trials
Table 2 shows a list of PARP inhibitors that are currently in clinical development [4]. A full
list of studies involving all tumor types can be found through the National Institute of
Health website, www.clinicaltrials.gov.
Iniparib is one of the first drugs looked at in the PARP inhibitor class. A phase II trial of inipar‐
ib in women with advanced ovarian or breast cancer compared the chemotherapeutic regi‐
men  carboplatin/gemcitabine  with  and  without  iniparib.  The  iniparib  arm  showed  an
improved rate of clinical benefit (56% vs 34%, P=0.01), increased rate of overall response (52%
vs 32%, P=0.02), prolonged median progression free survival (5.9 movs 3.6 mo, P=0.01), and in‐
creased median overall survival (12.3 mo vs 7.7 mo, P=0.01) [47]. However, a phase III trial of
Iniparib for women with triple negative breast cancer proved to be disappointing [48,49]. This
trial, which randomized 519 women with triple negative breast cancer to carboplatin with
gemcitabine versus carboplatin, gemcitabine plus iniparib demonstrated an increase in pro‐
gression-free survival among the iniparib arm (5.1 vs 4.1 months, with P=0.027), but did not
reach statistical significance. Patients were not stratified based on BRCA status, specific triple
negative breast cancer subtype, or level of expression of PARP proteins. More recent studies
suggest that Iniparib may not actually inhibit the PARP enzyme in vitro. One in particular
compared Iniparib to Olaparib and Veliparib [50]. Olaparib and Veliparib proved to inhibit
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formation of the poly-ADP-ribose polymer in intact cells, but Iniparib exhibited little or no
ability to inhibit poly(ADP-ribose) polymer formation in situ. Other experiments revealed Ini‐
parib’s inability to sensitize cells to cisplatin, gemcitabine and paclitaxel [51]. Iniparib’s actual
role may be modification of cysteine-containing proteins in tumor cells. If this is in fact the case,
failure of the Iniparib phase III trial should not be used to guide further decisions about other
PARP inhibitors. Keeping that in mind, Iniparib is continuing to be studied in a number of
ovarian cancer trials, some showing promise. A phase II trial examining Iniparib in combina‐
tion with gemcitabine/carboplatin in patients with platinum-resistant recurrent ovarian can‐
cer has to date shown a 25% overall response rate consisting of 8 out of 32 confirmed responses
[52]. Progression free survival of 6.4 months (95% CI, 3.0-NE) was demonstrated in an early
analysis. The PFS and ORR are significantly improved when compared to a previous study of
pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer with an ORR
of 11.7% and mean progression free survival of 3.1 months [53]. Once again, these patients
were not stratified based on their BRCA carrier status. A similar study looked at iniparib in
combination with gemcitabine/carboplatin in patients with platinum-sensitive recurrent ovar‐
ian cancer [54]. This study showed an ORR of 65%, consisting of 26 out of 40 patients, as well as
a median progression free survival of 9.5 months. Interestingly, there was no indication of a re‐
lationship between BRCA status and response.
Agent Route of
Administration
Trial Interests Side Effects
Iniparib IV Ovarian cancer, uterine carcinosarcoma, NSCLCFatigue, nausea, diarrhea, dizziness
Olaparib Oral Breast and ovarian cancer, the BRCA
population, other advanced solid tumors
Nausea, vomiting, fatigue, taste-
alteration, anorexia
Veliparib Oral TNBC and BRCA deficient breast and ovarian
cancer
Myelosuppression, fatigue
Rucaparib IV BRCA associated breast cancer, locally
advanced or metastatic breast cancer,
advanced ovarian cancer
Thrombocytopenia and neutropenia
INO-1001 IV Melanoma, p53 deficient cancer cells Myelosuppression, transaminitis
MK-4827 Oral Advanced solid tumors, ovarian cancer,
hematologic malignancies, advanced
melanoma, advanced glioblastoma
Fatigue, reversible pneumonitis,
myelosuppression,
thrombocytopenia
AZD-2461 Oral Single agent for refractory solid tumors
CEP-9722 Oral Single agent for advanced solid tumors
E7016 Oral Advanced solid tumors, melanoma,
glioblastoma
BMN-673 Oral Advanced solid tumors and hematologic
malignancies
Table 2. PARP Inhibitors in Clinical Development
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Olaparib, on the other hand, is a considered a bona-fide PARP inhibitor and has shown
promising results in phase II trials in the treatment of BRCA-deficient advanced ovarian
cancer. A recent study looked at oral Olaparib as a single agent, and its effect on BRCA posi‐
tive vs. BRCA wild-type patients in women with ovarian and breast cancer [55]. Women
with advanced high grade serous and/or undifferentiated ovarian carcinoma or triple-nega‐
tive breast cancer were enrolled and received olaparib 400 mg twice a day. 91 patients were
enrolled in this particular study, 65 with ovarian cancer and 26 with breast cancer. 63 of the
65 ovarian cancer cohorts had target lesions and were evaluable for objective response.
Among these 63 patients, 41% of BRCA carriers showed confirmed objective response (7 out
of 17 with 95% CI) and a surprising 24% of BRCA wild-type patients showed confirmed ob‐
jective response (11 of 46 with 95% CI). The 24% response of BRCA wild type patients sug‐
gests that Olaparib, if not all PARP inhibitors, may provide significant benefit for all patients
with ovarian cancer, and not only those with selective BRCA mutation. As mentioned
above, around 40-50% of ovarian cancers, in the absence of a mutation of the BRCA gene,
can affect the functional aspect of the BRCA proteins and ultimately homologous recombi‐
nation. It is for this reason that PARP inhibition likely shows benefit in not just the BRCA
mutated population, but a larger population that umbrellas deficient homologous repair.
However, for this particular study phase III trials are no longer scheduled to commence be‐
cause the interim analysis of survival did not show the desired benefit in relation to the ben‐
efit in progression free survival. Also, there were no confirmed objective responses reported
in the breast cancer patients.
A very similar 2-part study looked at single agent Olaparib, and compared doses (100mg vs.
400mg) in the treatment of advanced breast and ovarian cancer in BRCA deficient individu‐
als [56,57]. Among the 57 ovarian cancer patients, the overall response rate of olaparib
100mg BID was 12.5% with a clinical benefit rate of 16.7%. For the 400mg BID arm, ORR was
33% with a clinical benefit rate of 57.6%. Further stratification showed a response in both
platinum-sensitive individuals (38% ORR) and platinum-resistant individuals (30%).
Among the 54 breast cancer patients, the overall response of olaparib 100mg BID was 25%
with a progression free survival of 3.8months. For the 400mg BID arm, ORR was 42% with
PFS of 5.7 months.
Olaparib is also being looked at as maintenance therapy. A phase II trial studied Olaparib as
a maintenance therapy in relapsed serous ovarian cancer. The 265 enrolled patients had re‐
ceived at least 2 previous platinum based chemo regimens with eventual relapse [58]. Early
analysis has shown a 65% reduced risk of progression in the Olaparib arm, improving pro‐
gression free survival by 3.6 months (8.4 mo vs. 4.8). Patients were stratified based on BRCA
status, age, race, Jewish ethnicity, prior response to platinum regimen and relapse time, and
each subgroup showed an improved progression free survival in the Olaparib arm. Overall
survival data has not been analyzed.
Another study looking at differences in response to olaparib based on platinum-response
status [59]. This trial looked at oral olaparib as a single agent against advanced ovarian can‐
cer in 50 women with BRCA mutations. Results showed a 61.5% response rate in platinum-
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sensitive patients, a 41.7% response rate in platinum-resistant patients and 15.4% response
rate in platinum-refractory patients.
A randomized phase II trial in BRCA deficient advanced ovarian cancer (platinum interval<12
months) enrolled 97 women and looked at olaparib dosing, 200mg vs 400mg, and compared its
efficacy to pegylated liposomal doxorubicin [60]. Of the 32 low dose olaparib cohorts (200mg
BID), 38 % showed objective response with a median progression free survival of 6.5 months.
Of the 32 high dose (400mg BID) cohorts, 59% showed objective response with a median PFS of
8.8 months. These were compared to 33 women who received the standard pegylated liposo‐
mal doxorubicin, with an objective response of 38% and median PFS of 7.1 months, results that
were not clinically significant. This study, however, does not necessarily rule out Olaparib’s
action in BRCA deficient patients. Recent studies suggest that women with BRCA associated
ovarian cancer may demonstrate increased sensitivity to Doxil than previously reported in un‐
selected cases [61]. One study in particular showed a 57% response rate to PLD among BRCA
deficient patients, compared to 20% response rate among those with sporadic EOC. This re‐
sponse was associated with significantly improved progression-free and overall survival. Fur‐
thermore, the initial study was actually potentially comparing 2 drugs with particular benefit
in BRCA patients and though there is no clinically significant difference among them, they
each may show clinical significance when standing alone.
Another PARP inhibitor under investigation is Veliparib. A phase II trial of Veliparib in
combination with cyclophosphamide compared to single-agent cyclophosphamide is cur‐
rently ongoing [62]. This study examines Veliparib’s activity against advanced solid tumors
and lymphomas. Preliminary results show promising activity in the BRCA subset. Of the 35
patients enrolled, 7 have shown partial response and 6 have stable disease in the veliparib
arm. In another study veliparib with or without carboplatin was evaluated in patients with
stage III and IV BRCA-associated breast cancer [63]. Of the 22 patients enrolled, only 12
were eligible for evaluation. Complete response was seen in 2 patients and partial response
in 6 patients, with a clinical benefit of 75% seen.
A phase I study showed activity of veliparib and temozolomide in combination against
metastatic breast cancer [64]. Of the 41 patients enrolled, complete response was seen in 1
patient, partial response in 2, stable disease in 7 and disease progression in 14. BRCA muta‐
tion analysis is currently underway. Another study is currently looking at veliparib in com‐
bination with doxorubicin and cyclophosphamide for the treatment of breast cancer and
other solid tumors [65]. Of the 18 patients enrolled, 14 have breast cancer (including 5 with
BRCA mutations), 3 have ovarian cancer, and 1 other solid tumor. There has been objective
anti-tumor activity seen in the BRCA mutation carriers. With this particular regimen, dosing
was limited by myelosuppresion. Furthermore, although combination therapy has shown to
enhance chemotherapeutic effects, myelosuppression appears to be enhanced as well. More
than 50 clinical trials examining Veliparib are currently ongoing, looking at gynecologic can‐
cers, solid tumors, lymphomas, brain tumors, GI and prostate cancer. Most of these are cur‐
rently recruiting, with only a few in Stage II. It will be very exciting to see the end results of
these trials, specifically for our purposes, those involving BRCA analysis. Very few updates
have been given, as most of these are in the beginning stages.
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Agent Cancer Summary Prelim/Conclusions
Iniparib +
Carbo/Gem
[47]
Metastatic TNBC Phase 2
-123 enrolled with advanced
ovarian or breast cancer,
looked at C/G regimen vs.
C/G + Iniparib
-clinical benefit rate of 56% in Iniparib
arm vs. 34%
-Increased ORR (52% vs 32%)
-Increased median overall survival
(12.3 mo vs 7.7 mo)
-Increase in PFS among Iniparib arm
(5.1 vs. 4.1mo)
Iniparib +
Carbo/Gem
[48,49]
Metastatic TNBC Phase 3
-519 enrolled with TNBC and
looked at C/G regimen vs.
C/G + Iniparib
-increased median OS (11.8 vs 11.1
mo-did not reach clinical significance
*were not stratified on their BRCA
status
Iniparib
[50]
NA Study looked at ability of
Iniparib to inhibit the PARP
enzyme in vitro
-Olaparib and Veliparib proved to
inhibit formation of th epoly
-ADP-ribose polymer in intact cells, but
Iniparib exhibited little or no ability to
inhibit PARP in situ.
Iniparib +
Carbo/Gem
[52]
Platinum resistant
recurrent ovarian
cancer
48 patients with dx of
epithelial ovarian carcinoma,
follopian tube cancer, or
primary peritoneal carcinoma
with platinum-resistant
disease
-25% ORR, consisting of 8 out of 32
confirmed responses (compare to ORR
of 11.7% w/ PLD)
-PFS of 6.4 months (compare to PFS of
3.1 mo w/ PLD)
Iniparib + C/G
[54]
Platinum sensitive
recurrent ovarian
cancer
Single arm study
-41 patients with dx of
recurrent platinum sensitive
ovarian cancer
-ORR 65% (26 out of 40 patients)
-9.5mo. median PFS
-no indication of relationship between
BRCA status and objective response
Olaparib S.A.
[55]
Ovarian and breast
cancer
91 patients (65 with ovarian
ca, 26 with breast ca),
stratified based on BRCA
status
-41% of BRCA-m ovarian cancer
patients showed COR
-24% of BRCA-wt ovarian cancer
patients showed COR -no COR in
breast cancer patients
Olaparib S.A.
[59]
Ovarian cancer 50 patients enrolled and
stratified based on response
to platinum
-61.5% RR in platinum sensitive
-41.7% RR in platinum resistant
-15.4% RR in platinum refractory
Olaparib S.A.
[56]
Advanced breast
cancer in BRCA
deficient individuals
54 patients with breast cancer -ORR 42% with 400mgBID, PFS
5.7months -ORR 25% with 100mgBID,
PFS 3.8months
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Agent Cancer Summary Prelim/Conclusions
Olaparib S.A.
[57]
Advanced ovarian
cancer in BRCA
deficient individuals
57 patients with ovarian
cancer
-12.5% ORR of Olaparib 100mg
-33% ORR of Olaparib 400mg
-Response seen in both platinum
sensitive (38%) and platinum resistant
(30%) disease
-Clinical benefit rate 57.6% w
400mgBID, 16.7% w 100mgBID
Olaparib SA
[58]
Relapsed ovarian
cancer, platinum-
sensitive
265 enrolled with at least 2
previous platinum based
chemo regimens
-improved PFS by 3.6mo
-65% reduced risk of progression in
Olaparib arm
-no overall survival benefit
Olaparib SA vs.
PLD
[60]
BRCA deficient
advanced ovarian
cancer with platinum
interval <12 mo.
97 women enrolled, study
compared efficacy/safety of
olaparib vs. PLD
-in olaparib low dose group, 38%
showed COR, PFS 6.5mo
-high dose olaparib group, 59% COR,
PFS 8.8mo
-PLD group showed 38% COR, PFS
7.1mo
Veliparib with
Temozolomide
[64]
Metastatic triple
negative breast
cancer
41 patients -complete response in 1 patient,
partial response in 2 patients, stable
disease in 7, progression in 14
Veliparib with
Carboplatin
[63]
Stage IV breast
cancer
22 patients enrolled, 12
eligible for evaluation
-complete response in 2 patients,
partial response in 6 patients
-clinical benefit of 75% seen
Veliparib with
Doxo/
Cyclophospha
mide
[65]
Breast cancer and
other solid tumors
18 patients enrolled, 14 with
breast cancer (5 Brca+), 3 with
ovarian cancer and 1 other
-objective antitumor activity seen in
brca mutation carriers
-3/5 BRCA+ TNBC with partial
response
-stable disease at 12 weeks in 8 breast
cancer pt
-MTD 100mgBID
-dose limited by myelosuppression
Veliparib with
Cyclophospho
mide
[62]
Refractory solid
tumors and
lymphomas
35 patients -combination of Cyclophosphamide/
veliparib tolerated well
-promising activity in subset of BRCA+
individuals
S.A.- single agent; PFS-progression free survival; ORR-overall response rate; COR-confirmed objective response; BRCA-
WT-wild type; BRCA-m-mutant
Table 3. Clinical Trials [47-65]
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BMN-673 is the newest PARP inhibitor to be developed and is to date the most potent and
selective PARP inhibitor. It has been shown to be up to 700-fold more active in vitro in
BRCA deficient cell lines when compared to olaparib [66]. Phase I trials have yet to begin.
Rucaparib is another new PARP inhibitor being looked into. It is currently the focus of 3 dif‐
ferent clinical trials; examining its activity in combination with several different chemothera‐
peutic regimens, efficacy in BRCA-associated breast cancer, and treatment of patients with
locally advanced or metastatic breast and advanced ovarian cancer [4]. There a few other
PARP inhibitors that are currently being evaluated for efficacy and tolerability, and will
likely acquire more interest in the near future. Table 3 summarizes the findings of the PARP
inhibitors discussed above.
Phase I and II trials demonstrated PARP inhibitor’s favorable side effect profile; potentially
including fatigue, nausea, vomiting, and mood disturbance. Also, myelosuppression has
been noted in higher doses, especially when in combination with chemotherapy. These ad‐
verse effects are generally mild, especially in comparison with current chemotherapeutic
regimens.
8. Conclusion
PARP inhibitors have been increasingly studied. This new group of drugs has been shown
in multiple phase I and II trials to be efficacious with favorable side effect profiles. The pre‐
clinical data which suggested the effect of PARP inhibitors in BRCA deficient cells did not
take into account the much larger population of tumors deficient in homologous recombina‐
tion, with physically healthy yet functionally impaired BRCA genes. This new understand‐
ing has further raised the bar for the potential of this new class. PARP inhibitors have been
shown to increase progression-free-survival and overall response rate in a number of trials.
While there have indeed been some setbacks in the development of these new drugs, some
of the major concerns have been addressed. Though Iniparib’s phase III trial failure was ini‐
tially viewed as a major disappointment, later studies proved that Iniparib does not have
the same efficacy as its counterparts Olaparib/Veliparib, and ultimately may have no role in
PARP inhibition of single-strand break repair. Also, the discovery that Olaparib did not
show a clinically significant difference when compared to pegylated liposomal doxorubicin,
led to the detection of PLD as a particularly potent agent against BRCA deficient cells. So
rather than dismissing Olaparib’s effect as not clinically significant, this particular study en‐
couraged further investigation of PLD in this special population. Furthermore, the efficacy
of PARP inhibition is evident, but the ideal population that could benefit most from this
new class has yet to be determined. Future trials involving PARP inhibitors should undergo
extremely strict stratification, as it is crucial to reveal precisely which population stands to
benefit. Other concerns that need to be further investigated include mechanisms of resist‐
ance, use as frontline vs. maintenance vs. recurrent disease therapy, use in mono-therapy vs.
combination with chemo or combination with other targeted therapies.
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